Crossmark

Synergistic Immunoenhancement of Recombinant PBP2a Vaccine Candidate by Biogenic Selenium Nanoparticles and MF59 Against Methicillin-Resistant Staphylococcus Aureus

Crossref DOI link: https://doi.org/10.1007/s00284-026-04788-3

Published Online: 2026-02-27

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Daneshpajooh Rahmani, Mahya

Yazdi, Mohammad Hossein https://orcid.org/0000-0001-8567-8555
Haghighat, Setareh https://orcid.org/0000-0002-6605-5245
Zarrinpanah, Tina
License Information

Text and Data Mining valid from 2026-02-27

Version of Record valid from 2026-02-27
More Information

Article History

Received: 17 July 2025

Accepted: 11 February 2026

First Online: 27 February 2026

Declarations

:

: The authors declare that they have no competing interests.

: Not applicable.

: Animal study protocols were found to follow ethical principles, national norms, and standards for conducting Medical Research in Iran. The Islamic Azad Tehran Medical Sciences University, Pharmaceutical Faculty, approved all experimental procedures (IR.IAU.PS.REC.1400.239).

Document is current

Any future updates will be listed below